Fateme Kohansal Jajarm - Department Of Biology, Faculty Of Science, PayameNoor University, Mashhad, Iran
Amir Avan - Metabolic Syndrome Research Center, Mashhad University Of Medical Sciences, Mashhad, Iran , Cancer Research Center, Faculty Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran
Hassanian Mehr - Department Of Medical Biochemistry, Faculty Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran

Pancreatic-ductal-adenocarcinoma (PDAC) is amongst the most lethal malignancies, mainly because of its metastatic spread and multifactorial chemoresistance. In spite of the progress in surgical treatment, resulting in increasing resection rates and a decrease in treatment-related morbidity and mortality, the true figures of cure are even today below 3%. Curcumin is a major constituent of Curcuma longa,which exerts its anticancer properties in various human cancers including PC. However, instability at physiological pH, low solubility in water and rapid metabolism results in a low oral bioavailability ofcurcumin. The aim of present study was to evaluate the therapeutic potential of the phytosomal curcumin in PC in vitro model. MiaPaCa-2 cells were cultured in F12 medium with 10% FBS and 1%Penicillin and Streptomycin and incubated at 37 ° C and 5% CO2. In order to evaluate the viability of cells treated with different concentrations of phytosomal curcumin, the MTT assay was used. Curcumininhibited MiaPaCa-2 cell growth, as detected by MTT assay. The in vitro (IC50) phytosomal curcumin proliferation-inhibiting concentration was 1 mM. These data clearly establish the efficacy of phytosomalcurcumin in reducing human pancreatic cancer growth in the examined model. The therapeutic curcumin-based effects, with no limiting side-effects, suggest that phytosomal curcumin may be beneficial in patients with pancreatic cancer.

Gastric Cancer, Cancer Symptoms, Nutrition and Cancer, Cancer Treatment and Management, Drugs and Cancer